## Giulio Fortuna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1271302/publications.pdf

Version: 2024-02-01

430874 377865 1,313 62 18 34 h-index citations g-index papers 62 62 62 1727 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant. Biomolecules, 2021, 11, 1634.	4.0	O
2	The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris. Journal of Oral Pathology and Medicine, 2020, 49, 91-95.	2.7	6
3	Assessment of oral healthâ€related quality of life, measured by OHIPâ€14 and GOHAI, and psychological profiling in burning mouth syndrome: A caseâ€control clinical study. Journal of Oral Rehabilitation, 2020, 47, 42-52.	3.0	35
4	Autoimmune mucocutaneous blistering diseases in the south of Italy: a 25â€year retrospective study on 169 patients. Journal of Oral Pathology and Medicine, 2020, 49, 672-680.	2.7	8
5	Global research trends in complex oral sensitivity disorder: A systematic bibliometric analysis of the structures of knowledge. Journal of Oral Pathology and Medicine, 2020, 49, 565-579.	2.7	12
6	Global research trends in complex oral sensitivity disorder: A systematic bibliometric analysis of the framework. Journal of Oral Pathology and Medicine, 2020, 49, 555-564.	2.7	15
7	Dysgeusia in COVID-19: Possible Mechanisms and Implications. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 130, 344-346.	0.4	90
8	Oral Dysesthesia. , 2019, , 2081-2105.		4
9	Escalating dose of adalimumab as monotherapy to treat unusual giant and refractory oralâ€pharyngeal ulcerations in Crohn's disease. Dermatologic Therapy, 2019, 32, e12868.	1.7	2
10	The usefulness of YouTubeâ,¢ videos as a source of information on burning mouth syndrome. Journal of Oral Rehabilitation, 2019, 46, 657-665.	3.0	37
11	Seven novel <i>COL7A1</i> mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico. Clinical and Experimental Dermatology, 2018, 43, 579-584.	1.3	6
12	Management of reticular oral lichen planus patients with burning mouth syndrome-like oral symptoms: a pilot study. Journal of Dermatological Treatment, 2018, 29, 623-629.	2.2	11
13	Sleep quality and disturbances in patients with dystrophic epidermolysis bullosa. Dermatologica Sinica, 2018, 36, 1-7.	0.5	3
14	Oral Dysesthesia., 2018,, 1-25.		4
15	Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. European Journal of Clinical Pharmacology, 2017, 73, 1523-1537.	1.9	32
16	Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration. Journal of Investigative Dermatology, 2017, 137, 2298-2308.	0.7	27
17	Pain in Patients with Dystrophic Epidermolysis Bullosa: Association with Anxiety and Depression. Psychiatry Investigation, 2017, 14, 746.	1.6	9
18	Oral Dysesthesia., 2017, , 1-26.		0

#	Article	lF	CITATIONS
19	Cetrimide-induced oral mucositis: an unusual adverse drug reaction. European Journal of Clinical Pharmacology, 2016, 72, 1415-1416.	1.9	2
20	Role of dystrophic epidermolysis bullosa in anxiety, depression and selfâ€esteem: A controlled crossâ€sectional study. Journal of Dermatology, 2016, 43, 70-78.	1.2	11
21	"The discomfort is still there, but I do not care much about it!―The Therapeutic Role of the Transference Relationship between the Patient Suffering from Complex Oral Sensitivity Disorder and the Oral Health-care Provider. American Journal of Oral Medicine, 2016, 2, 11-20.	0.2	4
22	Clinical features of gingival lesions in patients with dystrophic epidermolysis bullosa: a cross-sectional study. Australian Dental Journal, 2015, 60, 18-23.	1.5	10
23	Evaluation of internal consistency of the epidermolysis bullosa oropharyngeal severity score (EBOS). Acta Odontologica Scandinavica, 2015, 73, 156-160.	1.6	2
24	Multiple primary melanomas versus single melanoma of the head and neck. Melanoma Research, 2014, 24, 267-272.	1.2	4
25	Linear immunoglobulin A disease and vancomycin: two real ancestral enemies?. British Journal of Dermatology, 2014, 171, 1248-1253.	1.5	4
26	Genotype–oropharyngeal phenotype correlation in Mexican patients with dystrophic epidermolysis bullosa. International Journal of Oral and Maxillofacial Surgery, 2014, 43, 491-497.	1.5	2
27	Clinical behaviour and longâ€ŧerm therapeutic response in orofacial granulomatosis patients treated with intralesional triamcinolone acetonide injections alone or in combination with topical pimecrolimus 1%. Journal of Oral Pathology and Medicine, 2013, 42, 73-81.	2.7	15
28	Oral plasmablastic lymphoma in an HIV-positive patient with an unusual survival rate. Infection, 2013, 41, 301-302.	4.7	5
29	Systemic Lupus Erythematosus. Dental Clinics of North America, 2013, 57, 631-655.	1.8	144
30	The largest family of the Americas with dominant dystrophic epidermolysis bullosa pruriginosa: A 18-year longitudinal genotype–phenotype study. Journal of Dermatological Science, 2013, 71, 217-221.	1.9	8
31	Measuring quality of life in epidermolysis bullosa in Mexico: Cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire. Journal of the American Academy of Dermatology, 2013, 69, 652-653.	1.2	15
32	Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: A multicenter development and reliability assessment. Journal of the American Academy of Dermatology, 2013, 68, 83-92.	1.2	28
33	Complex oral sensitivity disorder: a reappraisal of current classification of burning mouth syndrome. Oral Diseases, 2013, 19, 730-732.	3.0	23
34	Patterns of oral mucosa lesions in patients with epidermolysis bullosa: comparison and agreement between oral medicine and dermatology. Journal of Oral Pathology and Medicine, 2013, 42, 733-740.	2.7	14
35	Comment: Probable Clindamycin-Induced Ageusia, Xerostomia, and Burning Mouth Syndrome. Annals of Pharmacotherapy, 2012, 46, 1577-1578.	1.9	7
36	Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report. Oncology Letters, 2012, 4, 241-244.	1.8	8

#	Article	IF	CITATIONS
37	Drug-induced burning mouth syndrome: a new clinico-pathological entity?. Journal of Headache and Pain, 2012, 13, 685-686.	6.0	9
38	A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: AÂreal and separate nosological entity?. Journal of the American Academy of Dermatology, 2012, 66, 988-994.	1.2	81
39	Linear immunoglobulin A bullous dermatosis. Clinics in Dermatology, 2012, 30, 38-50.	1.6	170
40	Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?. Medical Oncology, 2012, 29, 2963-2965.	2.5	3
41	Multiple myeloma vs. breast cancer patients with bisphosphonatesâ€related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. Journal of Oral Pathology and Medicine, 2012, 41, 222-228.	2.7	16
42	Anxiety, Depression, and Pain in Burning Mouth Syndrome: First Chicken or Egg?. Headache, 2012, 52, 1019-1025.	3.9	90
43	Dysgeusia: An Atypical and Neglected Psychiatric Symptom Induced by Fibrillary Astrocytoma. American Journal of Medicine, 2011, 124, e1-e2.	1.5	4
44	Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. International Journal of Infectious Diseases, 2011, 15, e533-e540.	3.3	90
45	Burning Mouth Syndrome Responsive to Duloxetine: A Case Report: Table 1. Pain Medicine, 2011, 12, 466-469.	1.9	25
46	Clinical guidelines for the use of adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris: the oral medicine point of view. Journal of Oral Pathology and Medicine, 2011, 40, 359-360.	2.7	5
47	Frictional Keratoses on the Facial Attached Gingiva Are Rare Clinical Findings and Do Not Belong to the Category of Leukoplakia. Journal of Oral and Maxillofacial Surgery, 2011, 69, 1367-1374.	1.2	22
48	Oral histoplasmosis of a healthy man in a non-endemic area. Infection, 2011, 39, 497-498.	4.7	7
49	Oral field cancerization: Figure 1:. Cmaj, 2011, 183, 1622-1622.	2.0	3
50	Unexplained somatic comorbidities in patients with burning mouth syndrome: a controlled clinical study. Journal of Orofacial Pain, 2011, 25, 131-40.	1.7	32
51	Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, 837-843.	1.4	26
52	Oropharyngeal Pemphigus Vulgaris and Clinical Remission. American Journal of Clinical Dermatology, 2010, 11, 137-145.	6.7	21
53	Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis. European Journal of Clinical Pharmacology, 2009, 65, 1057-1059.	1.9	9
54	Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy. British Journal of Dermatology, 2009, 160, 468-470.	1.5	9

#	Article	IF	CITATIONS
55	Secondary syphilis mimicking pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 479-480.	2.4	12
56	Delayed immunologic evidence in pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1092-1093.	2.4	3
57	Gastric diffuse large B-cell lymphoma (DLBCL) exhibiting oral acanthosis nigricans and tripe palms. Digestive and Liver Disease, 2009, 41, 766-768.	0.9	2
58	Sunitinib Adverse Event: Oral Bullous and Lichenoid Mucositis. Annals of Pharmacotherapy, 2009, 43, 546-547.	1.9	2
59	Oral Crohn's Disease: A Favorable Clinical Response With Delayed-Release Triamcinolone Acetonide Intralesional Injections. American Journal of Gastroenterology, 2008, 103, 2954-2955.	0.4	13
60	Nikolsky's Sign on the Gingival Mucosa: A Clinical Tool for Oral Health Practitioners. Journal of Periodontology, 2008, 79, 2241-2246.	3 <b>.</b> 4	32
61	Small-Cell Lung Cancer and Necrolytic Migratory Erythema. New England Journal of Medicine, 2008, 359, 2731-2732.	27.0	11
62	Variations in Serum Hemoglobin, Albumin, and Electrolytes in Patients Receiving Intravenous Immunoglobulin Therapy. American Journal of Clinical Dermatology, 2007, 8, 291-299.	6.7	9